Myricitrin Ameliorates 6-Hydroxydopamine-Induced Dopaminergic Neuronal Loss in the Substantia Nigra of Mouse Brain
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Parkinson's disease (PD) is a chronic and progressive movement disorder, resulting from the degeneration of the nigrostriatal dopaminergic (DA) pathway. The cause of DA neuronal loss in PD is still unclear; however, accumulating evidence suggests that treatment with certain flavonoids can induce neuroprotective properties, such as activation of mammalian target of rapamycin complex 1 (mTORC1) and anti-inflammatory activities in animal models of PD. The bioflavonoid myricitrin is well known for its anti-inflammatory and antioxidant properties. However, it is unclear whether systemic treatment with myricitrin can protect neurons against neurotoxin-induced DA degeneration in vivo via the preservation of tyrosine hydroxylase (TH) activity and the induction of mTORC1 activation. Our results found no significant neuroprotective effect of 30 mg/kg myricitrin on 6-hydroxydopamine (6-OHDA)-induced neurotoxicity in the substantia nigra (SN) of mice. However, myricitrin treatment with 60 mg/kg protected DA neurons against 6-OHDA-induced neurotoxicity. Moreover, myricitrin treatment preserved TH enzyme activity and mTORC1 activation in nigral DA neurons in the SN of 6-OHDA-treated mice, and its treatment suppressed an increase in tumor necrosis factor-α expression in activated microglia. These results suggest that myricitrin may have neuroprotective properties linked to mTORC1 activation, preservation of TH enzyme activity, and anti-neuroinflammation for preventing DA neuronal degeneration in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuroinflammation in Parkinson’s disease: A target for neuroprotection?
Hirsch, E. C., & Hunot, S. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70062-6 · Cited by 1,984 · cited 1×
“5,35,36 This suggests that control of microglial activation may be important for protection of DA neurons during PD progression.”
Microglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism
Block, M. L., & Hong, J.-S. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.06.004 · Cited by 1,557
Alzheimer's Disease and Parkinson's Disease
Nussbaum, R. L., & Ellis, C. E. (2003) · New England Journal of Medicine · doi:10.1056/nejm2003ra020003 · Cited by 1,351
Tyrosine hydroxylase phosphorylation: Regulation and consequences
Dunkley, P. R., Bobrovskaya, L., Graham, M. E., Von Nagy‐Felsobuki, E. I., & Dickson, P. W. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02797.x · Cited by 455 · cited 2×
“25,30 Therefore, TH enzyme activity is very important to sustain DA in the brain.”
Kim, S. R., Kareva, T., Yarygina, O., Kholodilov, N., & Burke, R. E. (2012) · Molecular Therapy · doi:10.1038/mt.2011.213 · Cited by 107 · cited 3×
“The region encompassing the whole striatum was determined as previously described, 8 and the densitometric analysis was carried out by Science Lab 2001 Image Gauge (Fuji Film).”
Self-citationNam, J. H., Leem, E., Jeon, M.-T., Jeong, K. H., Park, J.-W., Jung, U. J., Kholodilov, N., Burke, R. E., Jin, B. K., & Kim, S. R. (2015) · Molecular Neurobiology · doi:10.1007/s12035-014-8729-2 · Cited by 76 · cited 1×
“…protect DA neurons via production of neurotrophic factors, which are important for preserving nigrostriatal DA projections in animal models of PD. 7–9 These evidences suggest that an agent, which can induce mTORC1 activation and anti-inflammatory activity in the brain, may protect DA neurons from…”
Kim, S. R., Chung, E. S., Bok, E., Baik, H. H., Chung, Y. C., Won, S. Y., Joe, E., Kim, T. H., Kim, S. S., Jin, M. Y., et al. (2010) · Journal of Neuroscience Research · doi:10.1002/jnr.22318 · Cited by 43 · cited 1×
“5,35,36 This suggests that control of microglial activation may be important for protection of DA neurons during PD progression.”
Self-citation
Cited by
Myricetin: A review of the most recent research
Song, X., Tan, L., Wang, M., Ren, C., Guo, C., Yang, B., Ren, Y., Cao, Z., Li, Y., & Pei, J. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111017 · Cited by 378
Beneficial Effects of Flavonoids Against Parkinson's Disease
Jung, U. J., & Kim, S. R. (2018) · Journal of Medicinal Food · doi:10.1089/jmf.2017.4078 · Cited by 150
“82 It is suggested that mTORC1 activation is required to protect DA neurons in animal models of PD, as it leads to the production of neurotrophic factors that are important for preserving nigrostriatal DA projections.”
Self-citationNatural Products as a Potential Modulator of Microglial Polarization in Neurodegenerative Diseases
Jin, X., Liu, M.-Y., Zhang, D.-F., Zhong, X., Du, K., Qian, P., Gao, H., & Wei, M.-J. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104253 · Cited by 109
Prothrombin Kringle-2: a potential inflammatory pathogen in the parkinsonian dopaminergic system
Leem, E., Jeong, K. H., Won, S.-Y., Shin, W.-H., & Kim, S. R. (2016) · Experimental Neurobiology · doi:10.5607/en.2016.25.4.147 · Cited by 16
“In addition to direct neuronal toxicity, 6-OHDA-induced neurotoxicity can promote microglial activation in nigrostriatal DA projection areas [32, 33], resulting in the production of neurotoxic proinflammatory cytokines [34, 35].”
BackgroundSelf-citation
Metadata
- Authors
- Kim, H. D., Jeong, K. H., Jung, U. J., & Kim, S. R.
- Venue
- Journal of Medicinal Food
- Publisher
- SAGE Publications
- Published
- 2016-04
- Volume
- 19
- Issue
- 4
- Pages
- 374-382
- ISSN
- 1096-620X (ISSN-L)
- 1557-7600
- OpenAlex
- W2308846837
- Cited by
- 40
- References
- 7
- FWCI
- 4.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.